More Related Content
What's hot
What's hot (20)
Viewers also liked
Similar to Ourotech Investor Deck Feb 2017
Similar to Ourotech Investor Deck Feb 2017 (20)
Recently uploaded
Recently uploaded (20)
Ourotech Investor Deck Feb 2017
- 1. Ourotech Cancer treatment with certainty
- 2. Here’s how breast cancer is being fought today
- 3. 1st line treatment Herceptin combination 2nd line treatment T-DM1 3rd line treatment Xeloda 4th line treatment Hormone therapy Example: HER2+ Breast Cancer
- 4. Drug Resistance: Every cancer has a different weakness
- 5. The Problem Multiple drugs target the same cancer subtype but they don’t work on all patients Tumors can be resistant due to: - Genetic resistance/mutation - Tumor microenvironment - Interaction with other cancer cells - Interaction with healthy cells
- 6. Take the guess work out of cancer treatment
- 7. The Solution Obtain patient tumor sample from biopsy Grow tumors in 96 well plate using proprietary hydrogel Test the effectiveness of drugs and combination treatments Calculate necessary human dosage from test results Treat the patient
- 8. Obtain patient tumor sample from biopsy Grow tumors in 96 well plate using proprietary hydrogel Test the effectiveness of drugs and combination treatments Calculate necessary human dosage from test results Treat the patient
- 9. Proof of Concept: IC50 Drug Tested: Doxorubicin Human IC50: 702nM Ourotech IC50: 600~650nM Alginate IC50: 200nM IC50: industry standard measure of drug resistance Ourotech can predict this better than the competition
- 10. Core Technology Genesis Hydrogel that mimics conditions inside patients’ bodies for Stage 3 and 4 breast, colon, and brain cancers Allows doctors to culture patient tumors outside the body, create 3D tumor models and test drug resistance on patient derived tumors
- 11. $500/patient 1 order of hydrogel allows doctors to perform in vitro testing for 1 patient. Hydrogel is a consumable.
- 12. Market TAM SAM SOM 14.1M New Cancer Diagnoses/Year Worldwide $7.05B Market 3.3M New Breast, Colorectal, Brain Cancer Diagnoses/Year Worldwide $1.65B Market 407K New Breast, Colorectal, Brain Cancer Diagnoses/Year in the US $204M Market
- 13. Team Duleeka Ranatunga, CEO Prof Jonathan Blay Prof Shirley Tang William Lin, Head of R&D Christina Ryu, Business Development Ali Nikdel, R&DMichael Kim, Head of Finance
- 14. Funding Roadmap Strategic partnership with hospitals for preclinical trials Strategic partnership with big pharma client for clinical trials and distribution Start generating revenue by pharmaceutical drug testing services Optimize product based on drug testing and preclinical results Seed Series A
- 15. Funding and Milestones Ask: $1.5M Runway: 18 months Milestones Finish preclinical trials IRB and begin FDA 510K clearance process Generate revenues from pharma clients Develop new prototypes and IP
- 16. Traction 2 patents pending 2 academic pilots 2 pharma pilots, sales to start May 2017 1 Pre Clinical Trial In Progress Partnership for marketing
- 17. 2 Year Product Development Roadmap Develop more humanized hydrogels Integrate hydrogels with microfluidics and bioreactors Use big data for better drug dosage prediction Train machine learning algorithms to predict drug resistance Test immuno- therapies